Skip to main content
OpenTrials
Completed

NCT Number: NCT07147842

Rutin Therapy Role in Reducing Ulcerative Colitis Severity

Ulcerative colitis (UC) is an inflammatory bowel disease characterized by oxidative stress and recurring inflammation in the colon. The condition can become chronic, spread, and lead to other complications.

A key player in the inflammation process is the NLRP3 inflammasome. This inflammasome's expression is heightened and activated by reactive oxygen species (ROS). Its activity is influenced by various factors, including the ubiquitin system, ion channels, and gut microbiota.

Rutin, a compound found in many fruits and vegetables, has been shown to have properties that help scavenge free radicals.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ulcerative Colitis Colitis Colitis, Ulcerative Colonic Diseases Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Benha University

Banhā, El Qalyoubia, 13511, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients presenting with symptoms suggestive of IBD;
  • Patients with positive microscopic mucosal changes consistent with UC.

Exclusion criteria

  • Patients with the presence of recurrent ulceration after surgical treatment, malignancy, or autoimmune disorders.

Treatment and study plan

Rutin 500 MG

Drug

Rutin 500 mg capsules twice daily for 30 days

Placebo

Other

Placebo Tablets

fecal calprotectin

Diagnostic Test

Fecal calprotectin level was measured using an ELISA kit .

Primary outcomes

  1. Success Rate of Treatment Regimens in improving the ulcerative colitis.

    Time frame: 3~4 Months

    The proportion of patients who achieved a Simple Clinical Colitis Activity Index (SCCAI) score of 5 or less at the end of the study, which reflects the effectiveness of the treatment.

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

Rutin Therapy Reduces Ulcerative Colitis Disease Activity By Inhibiting The NOD-Like Receptor Protein 3 (NLRP3) Inflammasome: A Molecular Assessment in a Case-Control Study

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Aug 29, 2025
Registry last updated
Aug 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.